Advertisement
Singapore markets open in 7 hours 49 minutes

  • Straits Times Index

    3,287.75
    -5.38 (-0.16%)
     

  • S&P 500

    5,031.19
    -40.44 (-0.80%)
     

  • Dow

    37,995.10
    -465.82 (-1.21%)
     

  • Nasdaq

    15,537.93
    -174.82 (-1.11%)
     

  • Bitcoin USD

    64,769.25
    -57.14 (-0.09%)
     

  • CMC Crypto 200

    1,389.67
    +7.10 (+0.51%)
     

  • FTSE 100

    8,078.86
    +38.48 (+0.48%)
     

  • Gold

    2,340.80
    +2.40 (+0.10%)
     

  • Crude Oil

    82.44
    -0.37 (-0.45%)
     

  • 10-Yr Bond

    4.6980
    +0.0460 (+0.99%)
     

  • Nikkei

    37,628.48
    -831.60 (-2.16%)
     

  • Hang Seng

    17,284.54
    +83.27 (+0.48%)
     

  • FTSE Bursa Malaysia

    1,569.25
    -2.23 (-0.14%)
     

  • Jakarta Composite Index

    7,155.29
    -19.24 (-0.27%)
     

  • PSE Index

    6,574.88
    +2.13 (+0.03%)
     

Xenon Pharmaceuticals to Present at the Goldman Sachs 44th Annual Global Healthcare Conference

Xenon Pharmaceuticals Inc.
·1-min read
Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc.

VANCOUVER, British Columbia, June 06, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present at the Goldman Sachs 44th Annual Global Healthcare Conference in Dana Point, CA.

Company Fireside Chat Presentation Details:

 

 

Date:

Monday, June 12, 2023

 

 

Time:

10:00 am Pacific Time (1:00 pm Eastern Time)

 

 

Webcast:

Register here

 

 

Presenters:

Ian Mortimer, President and CEO
Sherry Aulin, CFO

 

 

A live webcast of the company presentation will be available on the “Investors” section of Xenon's website and posted for replay following the event. The above listed dates and times are subject to change.

ADVERTISEMENT

About Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals (NASDAQ:XENE) is a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders. We are advancing a novel product pipeline of neurology therapies to address areas of high unmet medical need, with a focus on epilepsy. For more information, please visit www.xenon-pharma.com.

“Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.

Investor/Media Contact:
Jodi Regts
Xenon Pharmaceuticals Inc.
Phone: 604.484.3353
Email: investors@xenon-pharma.com